- Home
- VEL vs MLTX Comparison
VEL vs MLTX Comparison
Compare VEL & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- MLTX
- Stock Information
- Founded
- VEL 2004
- MLTX 2021
- Country
- VEL United States
- MLTX Switzerland
- Employees
- VEL N/A
- MLTX N/A
- Industry
- VEL Finance: Consumer Services
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- MLTX Health Care
- Exchange
- VEL Nasdaq
- MLTX Nasdaq
- Market Cap
- VEL 602.1M
- MLTX 595.6M
- IPO Year
- VEL 2020
- MLTX N/A
- Fundamental
- Price
- VEL $18.38
- MLTX $9.81
- Analyst Decision
- VEL Strong Buy
- MLTX Buy
- Analyst Count
- VEL 3
- MLTX 9
- Target Price
- VEL $21.67
- MLTX $37.63
- AVG Volume (30 Days)
- VEL 69.4K
- MLTX 5.7M
- Earning Date
- VEL 11-06-2025
- MLTX 11-07-2025
- Dividend Yield
- VEL N/A
- MLTX N/A
- EPS Growth
- VEL 26.95
- MLTX N/A
- EPS
- VEL 2.22
- MLTX N/A
- Revenue
- VEL $195,592,000.00
- MLTX N/A
- Revenue This Year
- VEL $3.99
- MLTX N/A
- Revenue Next Year
- VEL $29.69
- MLTX N/A
- P/E Ratio
- VEL $8.29
- MLTX N/A
- Revenue Growth
- VEL 44.29
- MLTX N/A
- 52 Week Low
- VEL $16.12
- MLTX $5.95
- 52 Week High
- VEL $20.98
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- VEL 50.99
- MLTX 28.37
- Support Level
- VEL $17.74
- MLTX $9.37
- Resistance Level
- VEL $18.73
- MLTX $10.11
- Average True Range (ATR)
- VEL 0.36
- MLTX 0.58
- MACD
- VEL 0.04
- MLTX 1.66
- Stochastic Oscillator
- VEL 54.70
- MLTX 46.98
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.